Healthcare Review: Genworth & Laboratory Corp. Soars, Array Biopharma Slumps On News
(Thomson Reuters ONE) -
U.S. Stocks were trading mostly higher on Wednesday in cautious trading
following mixed economic data did little to change views of the Federal
Reserve's policy decision in the afternoon, with the central bank seen as likely
to leave the door open to further stimulus. Several healthcare stocks are making
notable news at mid day on Wednesday.
Array Biopharma Inc. (NASDAQ:ARRY) shares slumped 14% after its ARRY-797 drug
failed to reduce pain better than an existing standard treatment, Oxycodone, in
a Phase II trial of osteoarthritis patients. However, ARRY-797 did did meet its
primary endpoints and reduced pain much more than a placebo.
Cell Therapeutics Inc (NASDAQ:CTIC) shares climbed 2.69% to $0.530 after the
company reported a second-quarter 2012 net loss of $58.6 million or $0.28 per
share, as compared to $22.5 million or $0.14 per share loss in the same quarter
previous year, primarily due to an increase in non-cash deemed dividends on
preferred stock issuances and operating expenses, which includes the acquisition
of pacritinib from S*BIO.
Theravance Inc (NASDAQ:THRX) reported second-quarter net loss of $37.12 million
or $0.42 per share, as compared to $25.05 million or $0.31 per share in the same
quarter last year. Total revenues plunged to $1.43 million, versus $6.39 million
in the prior-year quarter. Analysts expected loss of $0.44 per share on revenue
estimate of $1.97 million for the quarter.
Vical Incorporated (NASDAQ:VICL) reported second quarter revenues of $1.6
million, as compared to $0.8 million in the year ago period. The net loss was
$7.9 million, or $0.09 per share, for the second quarter of 2012, as compared
with $8.4 million, or $0.12 per share, for the same period last year.
Laboratory Corp. of America Holdings (NYSE:LH) shares soared 13.69% to $95.60
after the company announced the completion of its acquisition of MEDTOX
Scientific, Inc., effective July 31, 2012. At a special meeting held on July
31, 2012, MEDTOX's stockholders approved the acquisition and the transaction
closed promptly thereafter. MEDTOX stockholders will receive a letter of
transmittal from American Stock Transfer & Trust Company LLC as paying agent
with instructions on how to cash in their shares of MEDTOX common stock.
Genworth Financial Inc (NYSE:GNW) shares climbed 6.35% to $5.36 after the
company posted second quarter net income of $76 million or $0.16 per share, as
compared to a net loss of $136 million or $0.28 per share in the prior-year
quarter. Total revenues for the quarter declined to $2.52 billion from $2.66
billion in the same quarter last year. Analysts expected the company to report
earnings of $0.18 per share on consensus revenue estimate of $2.52 billion.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Equity Briefing via Thomson Reuters ONE
[HUG#1631297]
Datum: 01.08.2012 - 21:51 Uhr
Sprache: Deutsch
News-ID 170986
Anzahl Zeichen: 3536
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 157 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Healthcare Review: Genworth & Laboratory Corp. Soars, Array Biopharma Slumps On News"
steht unter der journalistisch-redaktionellen Verantwortung von
Equity Briefing (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
